Author

H. Beltran

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 9

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 8 Approach:experimental assay· 6 Assay:bulk RNA-seq· 5 Research Focus:cell type annotation· 5 Research Focus:differential expression· 4 Approach:statistical model· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:clustering· 2

Frequent Co-Authors

A. Sboner· 3 shared A. Zoubeidi· 3 shared D. Prandi· 3 shared Y. Chen· 3 shared A. Gopalan· 2 shared A. Sheahan· 2 shared E. Corey· 2 shared F. Demichelis· 2 shared

Activity by Year

2018-2024 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

A. Sboner

Mutual co-authors in cluster

Author profile →

9 papers

Recent·Most cited

A double-negative prostate cancer subtype is vulnerable to SWI/SNF-targeting degrader molecules

P. D. Thienger, I. Paassen, X. Yao, P. D. Rubin, M. Lehner, N. Lillis, A. Benjak, S. Shah, A. King-Yung Leung, S. de Brot, A. Naveed, B. Daniel, M. Shi, J. Tremblay, J. Triscott, , M. A. Rubin

This study identifies a SWI/SNF-targeting therapy effective against a double-negative prostate cancer subtype, showing it reduces viability in both AR-dependent and WNT-dependent models.

bioRxiv · Mar 24, 2024Cancer Biology

MYBL2 drives prostate cancer plasticity and identifies CDK2 as a therapeutic vulnerability in RB1-loss and neuroendocrine prostate cancer

L. Ellis, B. German, J. N. Singh, D. L. Burkhart, A. Sheahan, H. Bergom, K. L. Morel, H. Beltran, J. Hwang, K. Lawrenson

This study identifies MYBL2 as a master regulator of phenotypic plasticity in prostate cancer and shows CDK2 inhibition as a potential therapeutic strategy for MYBL2-driven tumors.

bioRxiv · Jan 31, 2024 · PreprintCancer Biology

Discovery and characterization of a first-in-field transcription factor BRN2 inhibitor for the treatment of neuroendocrine prostate cancer.

D. Thaper, R. Munuganti, A. Aguda, S. Kim, S.-y. Ku, O. Sivak, S. Kumar, S. Vahid, D. Ganguli, H. Beltran, C. M. Morrissey, E. Corey, A. Zoubeidi

This paper develops and characterizes B18-94, the first BRN2 inhibitor, showing efficacy in reducing NEPC tumor growth with no toxicity.

bioRxiv · May 4, 2022 · PreprintCancer Biology

Harbingers of Aggressive Prostate Cancer: Precision Oncology Case Studies

J. Cyrta, D. Prandi, A. Arora, D. H. Hovelson, A. Sboner, A. Rodriguez, T. Fedrizzi, H. Beltran, D. R. Robinson, A. Gopalan, L. True, P. Nelson, B. D. Robinson, J. M. Mosquera, S. Tomlins, , M. Rubin

This study identifies molecular features of primary prostate cancer and their relation to metastasis using genomic and histopathological analysis.

bioRxiv · Nov 30, 2021 · PreprintCancer Biology

Tribbles 2 confers enzalutamide resistance in prostate cancer by promoting lineage plasticity.

J. Monga, I. Adrianto, C. Rogers, S. Gadgeel, D. Chitale, J. Alumkal, H. Beltran, A. Zoubeidi, J. Ghosh

This study identifies Tribbles 2 as a driver of enzalutamide resistance in prostate cancer by promoting lineage plasticity and neuroendocrine differentiation.

bioRxiv · Mar 26, 2021Cancer Biology

Role of Specialized mSWI/SNF Complexes in Prostate Cancer Lineage Plasticity

J. Cyrta, A. Augspach, M. R. de Filippo, D. Prandi, P. Thienger, M. Benelli, V. Cooley, R. Bareja, D. Wilkes, S.-S. Chae, P. Cavaliere, N. Dephoure, A.-C. Uldry, S. B. Lagache, S. Cohen, , M. Rubin

The paper investigates the role of mSWI/SNF complexes in NEPC lineage plasticity using patient data and cell models, finding deregulated subunits and SMARCA4 overexpression linked to aggressive disease.

Nature Communications · Nov 3, 2020Peer-reviewedCancer Biology

Chromatin accessibility profiles of castration-resistant prostate cancers reveal novel subtypes and therapeutic vulnerabilities

F. Tang, S. Wang, C. K. Wong, C. J. Lee, S. Cohen, J. Park, C. E. Hill, K. Eng, R. Bareja, T. Han, E. M. Liu, A. Palladino, W. Di, D. Gao, W. Abida, , E. Khurana

This study identifies four subtypes of castration-resistant prostate cancer using ATAC-seq and RNA-seq data, revealing novel therapeutic targets and classification for 370 patients.

bioRxiv · Oct 26, 2020 · PreprintCancer Biology

Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer

S. C. Baca, D. Y. Takeda, J.-H. Seo, J. Hwang, S. Y. Ku, R. Arafeh, T. Arnoff, S. Agarwal, C. Bell, E. O'Connor, X. Qiu, S. Abu Alaiwi, R. I. Corona, M. A. S. Fonseca, C. Giambartolomei, , M. L. Freedman

The paper identifies FOXA1 reprogramming in NEPC and shows its role in maintaining NE lineage features through epigenomic profiling.

bioRxiv · Oct 23, 2020Cancer Biology

Proteomic and Genomic Signatures of Repeat-instability in Cancer and Adjacent Normal Tissues

E. Persi, D. Prandi, Y. I. Wolf, Y. Pozniak, C. Barbieri, P. Gasperini, H. Beltran, B. M. Faltas, M. A. Rubin, T. Geiger, E. V. Koonin, F. Demichelis, D. Horn

The paper quantifies repeat-instability in cancer and normal tissues using proteomic and genomic data, identifying tumor-specific signatures linked to progression and tumorigenic state.

bioRxiv · Dec 9, 2018Cancer Biology